Exhibit 10.2 PRIVATE AND CONFIDENTIAL (1) Arrow Electronics (UK) Limited a company registered in England and Wales under number 02582534 and whose registered office is at Edinburgh Way, Harlow, Essex, United Kingdom CM20 2DF ("the Company"); and (2)...Private And • February 1st, 2006 • Arrow Electronics Inc • Wholesale-electronic parts & equipment, nec • England
Re: COLLABORATIVE ENGAGEMENT AGREEMENTPrivate And • October 10th, 2015
This will confirm and constitute a memorandum of our understanding regarding our representation of you in connection with your separation and divorce. I agree to be your attorney in a Collaborative Process. I will not be your spouse's attorney, and nothing in this Agreement should be construed to give me any independent obligations to your spouse. Your spouse must have his/her own attorney in the process.
February 18, 2011 PRIVATE AND CONFIDENTIAL Mr. Ed Cofrancesco President International Assets Advisory, LLCPrivate And • March 4th, 2011 • Preferred Apartment Communities Inc • Real estate investment trusts
To: Basing Bidco Limited (“you”, “your”)Private And • March 15th, 2024 • New York
PRIVATE AND CONFIDENTIAL December 16, 2022 Sun Pharmaceutical Industries Limited SUN HOUSE, 201 B/1 Western Express Highway Goregaon (E) Mumbai 400063Private And • February 2nd, 2023 • Sun Pharmaceutical Industries LTD • Pharmaceutical preparations
This letter agreement (this “Agreement”) is entered into between Concert Pharmaceuticals, Inc. (the “Company”) and Sun Pharmaceutical Industries Limited (“Sun Pharma”) in connection with a possible negotiated acquisition of 100% of the outstanding capital stock of the Company by Sun Pharma (the “Transaction”) on the terms set forth in Sun Pharma’s revised proposal dated December 14, 2022. As an inducement to Sun Pharma’s efforts to enter into a definitive agreement providing for a Transaction, from the date of this letter through the Exclusivity Termination Time (as defined below), the Company agrees that it will not, and it will cause its controlled affiliates and representatives not to, (i) enter into or continue any negotiations with any party other than Sun Pharma and its affiliates (and their respective designees) (a “Third Party”) with respect to a possible acquisition of any capital stock or securities exercisable, convertible or exchangeable therefor (collectively, “Securities”
Re: Amendment to Non-Disclosure AgreementPrivate And • April 18th, 2014 • GTCR Valor Merger Sub, Inc. • Services-prepackaged software • Delaware
Reference is made to that certain Non-Disclosure Agreement, dated December 20, 2013 (the “Non-Disclosure Agreement”), by and between Vocus, Inc. (the Company”) and GTCR LLC (“GTCR”), a copy of which is attached hereto as Exhibit A. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Non-Disclosure Agreement.
March 8, 2014 PRIVATE AND CONFIDENTIAL Vocus, Inc. 12051 Indian Creek Court Beltsville, MD 20705Private And • April 18th, 2014 • GTCR Valor Merger Sub, Inc. • Services-prepackaged software
This letter agreement sets forth our understanding with respect to certain matters relating to our negotiations regarding a possible transaction (the “Possible Transaction”) between Vocus Inc. (the “Company”) and certain entities to be formed by GTCR LLC (the “Sponsor”). To complete our confirmatory due diligence and definitive documentation in an expedited manner, we require that the Company enter into a period of exclusivity with the Sponsor. During the Exclusivity Period, the Sponsor and its advisors will work diligently on all outstanding items to drive the transaction towards completion. The Sponsor and the Company hereby agree as set forth below.
STRICTLY PRIVATE AND CONFIDENTIALPrivate And • May 6th, 2020 • British Columbia
This binding letter agreement sets out the agreement of the Parties (as defined below) with respect to, among other things, the granting to BetterLife Pharma Inc., or such designated subsidiary of BetterLife Pharma Inc. as the Parties mutually agree upon (“BLF”) of certain exclusive rights in and to intellectual property relating to the AP-003 Program of Altum Pharmaceuticals Inc. (“Altum”): Interferon α2b (“IFN α2b”) for the Treatment of Coronavirus Disease of 2019 (COVID-19) (the “AP-003 Program”) (the granting of such rights, the “Transaction”).
EXHIBIT 10.4 PRIVATE AND CONFIDENTIAL ------------------------ April 8, 1998 Amtech Corporation 19111 Dallas Parkway, Suite 300 Dallas, TX 75281-3106 Attention: David P. Cook Re: Acquisition of Transportation Systems Group - LETTER OF INTENT Ladies...Private And • May 15th, 1998 • Amtech Corp • Communications equipment, nec
September 27, 1999Private And • February 18th, 2000 • Partminer Inc • New York
December 8, 2010 PRIVATE AND CONFIDENTIAL Mr. Ed Cofrancesco President International Assets Advisory, LLCPrivate And • December 14th, 2010 • Preferred Apartment Communities Inc • Real estate investment trusts
PRIVATE AND CONFIDENTIALPrivate And • December 12th, 2014
We appreciate the opportunity to present you with our qualifications to provide monitoring services in connection with the Settlement Agreement Regarding the Albuquerque Police Department dated October 31, 2014. Kroll’s unique blend of professionals, along with years of experience in the areas of investigations, monitoring, technology, forensic accounting, and our knowledge of police department operations and community policing, makes the firm well suited for any monitoring assignment contemplated by the Department of Justice and the City of Albuquerque.
PRIVATE AND CONFIDENTIALPrivate And • April 25th, 2024
Ares Capital Europe VI (E)(L) II Investments S.à r.l., Ares Capital Europe VI (E) II Holdings S.à r.l., Ares Capital Europe VI (E)(L) Investments S.á r.l., Ares Capital Europe VI (E) Holdings S.à r.l., Ares Capital Europe VI (E) II Investments S.à r.l., Ares Capital Europe VI (E) Investments S.à r.l., Ares Capital Europe VI (G)(L) Investments S.á r.l., Ares Capital Europe VI (G) Holdings S.à r.l. and Ares Capital Europe VI (G) Investments S.à r.l. as underwriters and as original lenders of the Facilities and original interim lenders in respect of the Interim Facilities (the “Underwriters” and together with the Arranger, the “Commitment Parties” or “we”).
